Benjamin Solomon

63.4k total citations · 17 hit papers
415 papers, 20.8k citations indexed

About

Benjamin Solomon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Benjamin Solomon has authored 415 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 292 papers in Pulmonary and Respiratory Medicine, 286 papers in Oncology and 77 papers in Cancer Research. Recurrent topics in Benjamin Solomon's work include Lung Cancer Treatments and Mutations (272 papers), Lung Cancer Research Studies (116 papers) and Colorectal Cancer Treatments and Studies (92 papers). Benjamin Solomon is often cited by papers focused on Lung Cancer Treatments and Mutations (272 papers), Lung Cancer Research Studies (116 papers) and Colorectal Cancer Treatments and Studies (92 papers). Benjamin Solomon collaborates with scholars based in Australia, United States and France. Benjamin Solomon's co-authors include Alice T. Shaw, Rebecca S. Heist, Lecia V. Sequist, Enriqueta Felip, Justin F. Gainor, Tony Mok, Keith D. Wilner, Alesha Thai, D. Ross Camidge and A. John Iafrate and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Benjamin Solomon

394 papers receiving 20.5k citations

Hit Papers

First-Line Crizotinib ver... 2009 2026 2014 2020 2014 2021 2009 2012 2020 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    2014 2.3k citations Benjamin Solomon, Yi‐Long Wu et al. profile →
  2. Lung cancer
    2021 1.6k citations Benjamin Solomon, Justin F. Gainor et al. profile →
  3. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
    2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
  4. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
    2012 976 citations Alice T. Shaw, Mari Mino–Kenudson et al. profile →
  5. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
    2020 649 citations Alice T. Shaw, Filippo de Marinis et al. profile →
  6. Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
    2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
  7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
    2017 487 citations Alice T. Shaw, Benjamin Besse et al. profile →
  8. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
    2015 468 citations Daniel B. Costa, Alice T. Shaw et al. Journal of Clinical Oncology profile →
  9. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 370 citations Benjamin Solomon et al. Annals of Oncology profile →
  10. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
    2019 365 citations Benjamin Solomon, A. John Iafrate et al. Annals of Oncology profile →
  11. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
    2018 336 citations Benjamin Solomon, Richard J. Young et al. profile →
  12. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 286 citations Benjamin Solomon et al. Annals of Oncology profile →
  13. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
    2018 285 citations Benjamin Solomon, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
  14. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
    2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →
  15. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
    2022 129 citations Benjamin Solomon, Filippo de Marinis et al. profile →
  16. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →
  17. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
    2024 118 citations Benjamin Solomon, Alice T. Shaw et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Benjamin Solomon 14.1k 12.7k 6.7k 4.3k 1.8k 415 20.8k
Luis Paz‐Ares 11.4k 0.8× 13.2k 1.0× 7.6k 1.1× 4.2k 1.0× 1.3k 0.7× 690 23.0k
Lesley Seymour 13.6k 1.0× 13.8k 1.1× 5.3k 0.8× 3.8k 0.9× 1.2k 0.7× 258 22.2k
Suresh S. Ramalingam 14.5k 1.0× 15.5k 1.2× 8.8k 1.3× 4.2k 1.0× 1.5k 0.8× 593 25.5k
Chandra P. Belani 14.2k 1.0× 13.4k 1.1× 6.3k 0.9× 2.4k 0.5× 1.0k 0.6× 458 22.0k
Byoung Chul Cho 12.9k 0.9× 13.2k 1.0× 5.7k 0.8× 3.2k 0.7× 1.2k 0.7× 689 19.8k
Keunchil Park 17.0k 1.2× 17.9k 1.4× 6.2k 0.9× 4.0k 0.9× 2.8k 1.5× 567 27.4k
Rafael Rosell 16.6k 1.2× 15.2k 1.2× 10.0k 1.5× 6.0k 1.4× 1.9k 1.1× 546 26.8k
Mark A. Socinski 14.6k 1.0× 15.1k 1.2× 4.9k 0.7× 3.0k 0.7× 1.0k 0.6× 518 22.3k
Giorgio V. Scagliotti 19.6k 1.4× 17.1k 1.4× 8.4k 1.3× 5.3k 1.2× 1.5k 0.8× 480 29.7k
Neal I. Lindeman 13.2k 0.9× 11.6k 0.9× 8.1k 1.2× 5.8k 1.3× 2.6k 1.5× 172 22.4k

Countries citing papers authored by Benjamin Solomon

Since Specialization
Citations

This map shows the geographic impact of Benjamin Solomon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Solomon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Solomon more than expected).

Fields of papers citing papers by Benjamin Solomon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Solomon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Solomon. The network helps show where Benjamin Solomon may publish in the future.

Co-authorship network of co-authors of Benjamin Solomon

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Solomon. A scholar is included among the top collaborators of Benjamin Solomon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Solomon. Benjamin Solomon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fantoni, A, Lydia Warburton, Benjamin Solomon, et al.. (2024). Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT). Clinical Lung Cancer. 25(5). 449–459.
2.
Rafiq, Meena, Allison Drosdowsky, Benjamin Solomon, et al.. (2024). Trends in primary care blood tests prior to lung and colorectal cancer diagnosis—A retrospective cohort study using linked Australian data. Cancer Medicine. 13(14). e70006–e70006. 2 indexed citations
3.
Solomon, Benjamin, Yi‐Long Wu, Rafał Dziadziuszko, et al.. (2024). 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Annals of Oncology. 35. S775–S775. 1 indexed citations
4.
Horinouchi, Hidehito, Benjamin Solomon, Yi‐Long Wu, et al.. (2024). OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 19(10). S39–S39. 1 indexed citations
5.
Armstrong, Andrew J., Ravit Geva, Hyun Cheol Chung, et al.. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Investigational New Drugs. 42(1). 145–159. 33 indexed citations
6.
Alexander, Michael J., Michael Faltys, Lydia Warburton, et al.. (2023). 538P First-line chemoimmunotherapy for metastatic thymic carcinoma. Annals of Oncology. 34. S1679–S1680.
7.
Negrão, Marcelo V., Philippe A. Cassier, Benjamin Solomon, et al.. (2023). MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. Journal of Thoracic Oncology. 18(11). S117–S118. 16 indexed citations
8.
Wirth, Lori J., Vivek Subbiah, Francis P. Worden, et al.. (2023). 2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001. Annals of Oncology. 34. S1147–S1148. 3 indexed citations
9.
Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations
10.
Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →
11.
Degeling, Koen, Nancy N. Baxter, Jon Emery, et al.. (2021). An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic. Asia-Pacific Journal of Clinical Oncology. 17(4). 359–367. 56 indexed citations
12.
Solomon, Benjamin, Richard J. Young, Mathias Bressel, et al.. (2018). Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research. 6(3). 295–304. 100 indexed citations
13.
Weeden, Clare E., Aliaksei Z. Holik, Richard J. Young, et al.. (2017). Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 16(8). 1610–1622. 19 indexed citations
14.
Hunter, Francis W., Richard J. Young, Zvi Shalev, et al.. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research. 75(19). 4211–4223. 59 indexed citations
15.
Gainor, Justin F., Daniel Shao-Weng Tan, Benjamin Solomon, et al.. (2015). Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clinical Cancer Research. 21(12). 2745–2752. 135 indexed citations
16.
Mileshkin, Linda, Rodney J. Hicks, Brett Hughes, et al.. (2011). Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research. 17(10). 3304–3315. 106 indexed citations
17.
Azad, Arun, Susan Jackson, Carleen Cullinane, et al.. (2011). Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells. Molecular Cancer Research. 9(12). 1696–1707. 51 indexed citations
18.
Young, Richard J., Danny Rischin, Richard Fisher, et al.. (2011). Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 20(6). 1230–1237. 70 indexed citations
19.
Rischin, Danny, Richard J. Young, Richard Fisher, et al.. (2010). Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology. 28(27). 4142–4148. 571 indexed citations breakdown →
20.
Shaw, Alice T., Beow Y. Yeap, Mari Mino–Kenudson, et al.. (2009). Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology. 27(26). 4247–4253. 1463 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Chandra P. Belani Breakdown of academic impact, for papers by Byoung Chul Cho Breakdown of academic impact, for papers by Keunchil Park Breakdown of academic impact, for papers by Rafael Rosell Breakdown of academic impact, for papers by Mark A. Socinski Breakdown of academic impact, for papers by Giorgio V. Scagliotti Breakdown of academic impact, for papers by Neal I. Lindeman
Rankless by CCL
2026